Φορτώνει......
Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy
BACKGROUND AND PURPOSE: Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated. METHODS: Eighty-five patients received perampane...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Clin Neurol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Korean Neurological Association
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6031997/ https://ncbi.nlm.nih.gov/pubmed/29971974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3988/jcn.2018.14.3.296 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|